Personalised health care, the need for reassessment. A HTA perspective far beyond cost-effectiveness

Italian Journal of Public Health

Volumn 9, Issue 4, 2012, Pages

  Gutiérrez Ibarluzea, Iñaki ^a  

^a Basque Government   (Spain)

Author keywords

HTA; Personalised health care

Indexed keywords

EID: 84871547798     PISSN: 17237815     EISSN: None     Source Type: Journal    
DOI: 10.2427/8653     Document Type: Article

References (27)

1. Cesuroglu T, van Ommen B, Malats N, et al. Public health perspective: from personalized medicine to personal health. Personal Med 2012; 9: 115-9
2. International Network of Agencies of Health Technology Assessment: INAHTA glossary. Available from: http://www.inahta.org/HTA/Glossary/ (accessed on August 2012)
3. Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract. 2011; 7 (Suppl 3): 18s-24s. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092460/pdf/jop18s.pdf (accessed on October 2012)
4. Goodman CS. HTA 101: Introduction to Health Technology Assessment - The Lewin Group, Falls Church, Virginia, 2004. Available from: http://www.nlm.nih.gov/nichsr/hta101/hta101.pdf (accessed on August 2012)
5. Brand A. Public Health Genomics and Personalized Healthcare: a pipeline from cell to society Drug Metab Drug Interact 2012; 27(3): 121-3
6. Cancer Care Ontario. Mapping a Way Through the Double Helix. Making sense of personalized medicine for Ontario's cancer system. May 2011. Available from: http://www.cqco.ca/common/pages/UserFile.aspx?fileId=98415 (accessed on October 2012)
7. Scottish Medicines Consortium horizon scanning initiative. Available from: http://www.scottishmedicines.org.uk/ (accessed on October 2012)
8. AHRQ horizon scanning system. Available from: http://effectivehealthcare.ahrq.gov/index.cfm/who-is-involvedin-the-effective-health care-program1/ahrq-horizonscanning-system/ (accessed on October 2012)
9. Lampe K, Mäkelä M, Garrido MV, et al. European network for Health Technology Assessment (EUnetHTA). The HTA core model: a novel method for producing and reporting health technology assessments. Int J Technol Assess Health Care. 2009; 25 (Suppl 2): 9-20
10. Varela Lema L, Ruano Raviña A, Cerdá Mota T, et al. Post-introduction Observation of Health Technologies. A methodological guideline. Abridged version. Quality Plan for the National Health System. Galician Health Technology Assessment Agency; 2007. HTA Reports: avalia-t No. 2007/02 Available from: http://www.sergas.es/docs/Avalia-t/Post-introObs.pdf (accessed on August 2012)
11. Ruano Raviña A, Velasco González M, Varela Lema L, et al. Identification, prioritisation and assessment of obsolete health technologies. A methodological guideline. Quality Plan for the National Health System. Galician Health Technology Assessment Agency; 2007. HTA Reports: avalia-t No. 2007/01 Available from: http://www.sergas.es/docs/Avalia-t/ObsoleteTechMemFinal.pdf (accessed on August 2012)
12. Becla L, Lunshof JE, Gurwitz D, et al. Health technology assessment in the era of personalized health care. Int J Technol Assess Health Care. 2011; 27(2): 118-26
13. Li YY, Jones SJ. Drug repositioning for personalized medicine. Genome Med. 2012; 4(3): 27
14. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924-6
15. Ibargoyen-Roteta N, Gutiérrez-Ibarluzea I, Rico- Iturrioz R, et al. The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implement.Sci. 2010; 5: 48. Available from: http://www.implementationscience.com/content/5/1/48 (accessed on August 2012)
16. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64(4): 383-94
17. Márquez Calderón S, Castilla Alcalá JA, Briones Pérez de la Blanca E, et al. Guide for decision-making on the introduction of new genetic tests in the National Health System (GEN Guide). Madrid: Plan Nacional para el SNS del MSC. Agencia de Evaluación de tecnologías Sanitarias de Andalucía; 2006. Informes de Evaluación de Tecnologías Sanitarias. AETSA 2006/04. Available from: http://www.juntadeandalucia.es/salud/servicios/contenidos/aetsa/pdf/___AETSA_2006-04_GEN.pdf (accessed on October 2012)
18. Velasco-Garrido M, Mangiapane S. Surrogate outcomes in health technology assessment: an international comparison. Int J Technol Assess Health Care. 2009; 25(3): 315-22
19. Lenoir-Wijnkoop I, Dapoigny M, Dubois D, et al. Nutrition economics - characterising the economic and health impact of nutrition. Br J Nutr. 2011; 105(1): 157-66
20. National Human Genome Research Institute of the USA, 2012. Available from: http://www.genome.gov/27541954 (accessed on August 2012)
21. Report of the Secretary's Advisory Committee on Genetics, Health, and Society. Coverage and Reimbursement of Genetic Tests and Services. 2006. Available from: http://oba.od.nih.gov/oba/sacghs/reports/CR_report.pdf (accessed on August 2012)
22. Postma MJ, Boersma C, Vandijck D, et al. Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2011; 11(4): 367-9. Available from: http://www.expert-reviews.com/doi/full/10.1586/erp.11.50 (accessed on October 2012)
23. Pricewaterhouse Coopers. Personalised Medicine in European Hospitals. 2011. Available from: http://kc3.pwc.es/local/es/kc3/publicaciones.nsf/V1/765DD8AB19C2C116C1257991002E2984/$FILE/Persmedicine.pdf (accessed on August 2012)
24. European Commission Health Research Directorate. Personalised medicine. Opportunities and challenges for European healthcare. 2011. Available from: http://ec.europa.eu/research/health/pdf/13th-europeanhealth-forum-workshop-report_en.pdf (accessed on August 2012)
25. Lewis GH. Impactibility models: identifying the subgroup of high-risk patients most amenable to hospital-avoidance programs. Milbank Q. 2010; 88(2): 240-55
26. Marchant GE, Milligan RJ, Wihelmi B. Legal pressures and incentives for personalized medicine. Personalized Medicine. 2006; 3(4): 391-7
27. Testori Coggi P. A European view on the future of personalised medicine in the EU. Eur J Public Health 2011; 21: 6-7. Available from: http://eurpub.oxfordjournals.org/content/21/1/6.full (accessed on August 2012)